In the past week, BNTC stock has gone up by 6.64%, with a monthly decline of -15.63% and a quarterly surge of 4.94%. The volatility ratio for the week is 11.52%, and the volatility levels for the last 30 days are 9.44% for Benitec Biopharma Inc The simple moving average for the last 20 days is -8.97% for BNTC stock, with a simple moving average of 8.87% for the last 200 days.
Is It Worth Investing in Benitec Biopharma Inc (NASDAQ: BNTC) Right Now?
Moreover, the 36-month beta value for BNTC is 0.39. Analysts have varying opinions on the stock, with 4 analysts rating it as a “buy”, 3 as “overweight”, 0 as “hold”, and 0 as “sell”.
The public float for BNTC is 24.55M and currently, short sellers hold a 2.15% of that float. On July 04, 2025, BNTC’s average trading volume was 101.18K shares.
BNTC stock’s latest price update
Benitec Biopharma Inc (NASDAQ: BNTC) has seen a rise in its stock price by 3.38% in relation to its previous close of $12.74. However, the company has experienced a 6.64% gain in its stock price over the last five trading sessions. zacks.com reported 2025-06-16 that If you are looking for stocks that are well positioned to maintain their recent uptrend, Benitec Biopharma (BNTC) could be a great choice. It is one of the several stocks that passed through our “Recent Price Strength” screen.
Analysts’ Opinion of BNTC
Many brokerage firms have already submitted their reports for BNTC stocks, with H.C. Wainwright repeating the rating for BNTC by listing it as a “Buy”. The predicted price for BNTC in the upcoming period, according to H.C. Wainwright is $28 based on the research report published on December 16, 2024 of the previous year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see BNTC reach a price target of $30. The rating they have provided for BNTC stocks is “Outperform” according to the report published on December 13th, 2024.
Guggenheim gave a rating of “Buy” to BNTC, setting the target price at $17 in the report published on September 12th of the previous year.
BNTC Trading at -7.72% from the 50-Day Moving Average
After a stumble in the market that brought BNTC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -23.21% of loss for the given period.
Volatility was left at 9.44%, however, over the last 30 days, the volatility rate increased by 11.52%, as shares sank -14.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -4.46% lower at present.
During the last 5 trading sessions, BNTC rose by +6.64%, which changed the moving average for the period of 200-days by +61.60% in comparison to the 20-day moving average, which settled at $14.47. In addition, Benitec Biopharma Inc saw 81.31% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BNTC starting from SUVRETTA CAPITAL MANAGEMENT, L, who purchase 16,497 shares at the price of $12.83 back on Mar 31 ’25. After this action, SUVRETTA CAPITAL MANAGEMENT, L now owns 8,807,805 shares of Benitec Biopharma Inc, valued at $211,736 using the latest closing price.
SUVRETTA CAPITAL MANAGEMENT, L, the Director of Benitec Biopharma Inc, purchase 900,000 shares at $13.00 during a trade that took place back on Mar 26 ’25, which means that SUVRETTA CAPITAL MANAGEMENT, L is holding 8,793,245 shares at $11,700,000 based on the most recent closing price.
Stock Fundamentals for BNTC
The total capital return value is set at -0.31%. Equity return is now at value -48.57%, with -44.07% for asset returns.
Based on Benitec Biopharma Inc (BNTC), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -19.47. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -36.62.
Currently, EBITDA for the company is -22.49 million with net debt to EBITDA at 3.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.80.
Conclusion
To wrap up, the performance of Benitec Biopharma Inc (BNTC) has been better in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
